We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
Veeva Systems beat Q2 estimates, raised its fiscal 2027 outlook and advanced Vault CRM adoption.
VEEV has more than 180 Vault CRM customers live, with commitments from 12 of the top 20 biopharmas.
Veeva Systems' AI push is advancing, but market saturation and competition could constrain CRM growth.
Veeva Systems Inc. (VEEV - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid second-quarter fiscal 2027 performance and CRM migrations, is expected to contribute further. However, market saturation remains a cause for concern.
This Zacks Rank #3 (Hold) company’s shares have gained 27.6% in the year-to-date period compared with 15.8% growth of the industry. The S&P 500 composite has increased 14.5% during the said time frame.
The renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $45.74 billion. The company anticipates 35% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 5.7%.
Image Source: Zacks Investment Research
Reasons Favoring VEEV’s Growth
Enterprise CRM Migrations Expanding Account Footprint: Vault CRM adoption continued to advance in the second quarter of fiscal 2027, when Veeva Systems recorded its best CRM quarter and added two top-20 biopharma selections. Management said that Veeva Systems now has 12 of the top 20 CRM commitments, with two decisions remaining, up from 10 wins in the prior quarter.
More than 180 customers are live on Vault CRM, and one top-20 customer has enabled AI across its full field force. Commercial subscription revenues rose 13% year over year to $347.4 million, with management citing growth across CRM, content, data, Crossix and Ostro. The expanding live base supports ongoing migrations and creates opportunities to attach adjacent commercial applications as customers consolidate workflows on Vault.
Diversified Platform Driving Durable Growth:Veeva Systems’ long-term growth story is increasingly tied to its position at the center of life sciences digital transformation. The company operates across a broad set of markets spanning clinical development, quality management, regulatory operations, safety, commercial engagement and data analytics. Veeva Systems’ Development Cloud portfolio is particularly well-positioned as pharmaceutical companies seek integrated platforms that connect clinical data, trial operations, quality processes and regulatory functions within a unified ecosystem.
Growth is being fueled by newer product areas that remain in the early stages of penetration, including clinical data management, randomization and trial supply management, drug safety and laboratory information management systems. Management believes these businesses have a significant runway as customers increasingly favor end-to-end platforms over fragmented point solutions.
Strong Q2 Results: VEEV delivered better-than-expected second-quarter fiscal 2027 results, with both earnings and revenues surpassing the Zacks Consensus Estimate. The company also raised its full-year outlook, supported by solid execution across Commercial Solutions and R&D and Quality Solutions. Vault CRM continued to gain traction, achieving a record quarter with more than 180 customers live, including five of the top 20 biopharma companies. Two additional top 20 biopharmas and one large enterprise biopharma committed to the platform in August, bringing total top 20 commitments to 12 globally. A leading biopharma also deployed Vault CRM and Agentic Call Report across its entire U.S. field team, highlighting growing enterprise adoption.
Veeva Systems also advanced its artificial intelligence initiatives, with Veeva Falcon, its agentic labor platform for clinical, regulatory and safety functions, attracting five early adopters and remaining on track for initial go-lives in 2026. The acquisition of Copli and launch of Veeva Falcon MLR further strengthen the company's capabilities in automating content reviews. Meanwhile, Vault AI expanded its standard agent offerings and introduced advanced tools for custom agent development.
Although strong customer interest in Falcon presents a potential growth opportunity, product readiness and successful early-adopter deployments remain key near-term priorities. Overall, continued CRM adoption and AI-driven innovation could support Veeva Systems' long-term growth, although the commercial impact of newer offerings will depend on execution and broader customer adoption.
Factor That May Offset VEEV’s Gains
Market Saturation: The life sciences industry, Veeva Systems' primary market for its CRM solutions, is facing increasing saturation as digital transformation and CRM adoption have become widespread across pharmaceutical and biotech companies. Many large enterprises have already implemented Veeva Systems' CRM software or similar solutions, leaving fewer untapped opportunities for new customer acquisition.
Additionally, as smaller biotech firms and generics manufacturers enter the market, they may seek more cost-effective or niche CRM alternatives rather than Veeva Systems' premium offerings. This saturation, combined with heightened competition from both traditional CRM providers and emerging AI-powered platforms, could limit Veeva Systems' ability to maintain its historical CRM sales growth rates.
Estimate Trend
Veeva Systems is witnessing a stable estimate revision trend for fiscal 2027. In the past 30 days, the Zacks Consensus Estimate for fiscal 2027 earnings per share (EPS) has remained stable at $9.22.
The Zacks Consensus Estimate for third-quarter fiscal 2027 revenues is pegged at $933.8 million, indicating a 15.1% improvement from the year-ago quarter’s reported number. The consensus mark for fiscal third-quarter EPS is pegged at $2.33, implying a 14.2% improvement year over year.
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. West Pharmaceutical’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
Key Takeaways
Veeva Systems Inc. (VEEV - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid second-quarter fiscal 2027 performance and CRM migrations, is expected to contribute further. However, market saturation remains a cause for concern.
This Zacks Rank #3 (Hold) company’s shares have gained 27.6% in the year-to-date period compared with 15.8% growth of the industry. The S&P 500 composite has increased 14.5% during the said time frame.
The renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $45.74 billion. The company anticipates 35% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 5.7%.
Image Source: Zacks Investment Research
Reasons Favoring VEEV’s Growth
Enterprise CRM Migrations Expanding Account Footprint: Vault CRM adoption continued to advance in the second quarter of fiscal 2027, when Veeva Systems recorded its best CRM quarter and added two top-20 biopharma selections. Management said that Veeva Systems now has 12 of the top 20 CRM commitments, with two decisions remaining, up from 10 wins in the prior quarter.
More than 180 customers are live on Vault CRM, and one top-20 customer has enabled AI across its full field force. Commercial subscription revenues rose 13% year over year to $347.4 million, with management citing growth across CRM, content, data, Crossix and Ostro. The expanding live base supports ongoing migrations and creates opportunities to attach adjacent commercial applications as customers consolidate workflows on Vault.
Diversified Platform Driving Durable Growth:Veeva Systems’ long-term growth story is increasingly tied to its position at the center of life sciences digital transformation. The company operates across a broad set of markets spanning clinical development, quality management, regulatory operations, safety, commercial engagement and data analytics. Veeva Systems’ Development Cloud portfolio is particularly well-positioned as pharmaceutical companies seek integrated platforms that connect clinical data, trial operations, quality processes and regulatory functions within a unified ecosystem.
Growth is being fueled by newer product areas that remain in the early stages of penetration, including clinical data management, randomization and trial supply management, drug safety and laboratory information management systems. Management believes these businesses have a significant runway as customers increasingly favor end-to-end platforms over fragmented point solutions.
Strong Q2 Results: VEEV delivered better-than-expected second-quarter fiscal 2027 results, with both earnings and revenues surpassing the Zacks Consensus Estimate. The company also raised its full-year outlook, supported by solid execution across Commercial Solutions and R&D and Quality Solutions. Vault CRM continued to gain traction, achieving a record quarter with more than 180 customers live, including five of the top 20 biopharma companies. Two additional top 20 biopharmas and one large enterprise biopharma committed to the platform in August, bringing total top 20 commitments to 12 globally. A leading biopharma also deployed Vault CRM and Agentic Call Report across its entire U.S. field team, highlighting growing enterprise adoption.
Veeva Systems also advanced its artificial intelligence initiatives, with Veeva Falcon, its agentic labor platform for clinical, regulatory and safety functions, attracting five early adopters and remaining on track for initial go-lives in 2026. The acquisition of Copli and launch of Veeva Falcon MLR further strengthen the company's capabilities in automating content reviews. Meanwhile, Vault AI expanded its standard agent offerings and introduced advanced tools for custom agent development.
Although strong customer interest in Falcon presents a potential growth opportunity, product readiness and successful early-adopter deployments remain key near-term priorities. Overall, continued CRM adoption and AI-driven innovation could support Veeva Systems' long-term growth, although the commercial impact of newer offerings will depend on execution and broader customer adoption.
Factor That May Offset VEEV’s Gains
Market Saturation: The life sciences industry, Veeva Systems' primary market for its CRM solutions, is facing increasing saturation as digital transformation and CRM adoption have become widespread across pharmaceutical and biotech companies. Many large enterprises have already implemented Veeva Systems' CRM software or similar solutions, leaving fewer untapped opportunities for new customer acquisition.
Additionally, as smaller biotech firms and generics manufacturers enter the market, they may seek more cost-effective or niche CRM alternatives rather than Veeva Systems' premium offerings. This saturation, combined with heightened competition from both traditional CRM providers and emerging AI-powered platforms, could limit Veeva Systems' ability to maintain its historical CRM sales growth rates.
Estimate Trend
Veeva Systems is witnessing a stable estimate revision trend for fiscal 2027. In the past 30 days, the Zacks Consensus Estimate for fiscal 2027 earnings per share (EPS) has remained stable at $9.22.
The Zacks Consensus Estimate for third-quarter fiscal 2027 revenues is pegged at $933.8 million, indicating a 15.1% improvement from the year-ago quarter’s reported number. The consensus mark for fiscal third-quarter EPS is pegged at $2.33, implying a 14.2% improvement year over year.
Key Picks
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. West Pharmaceutical’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.